Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
VVOS Stock | USD 4.17 0.16 3.99% |
Slightly above 56% of all Vivos Therapeutics' private investors are looking to take a long position. The analysis of overall sentiment of trading Vivos Therapeutics stock suggests that some investors are interested at this time. Vivos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Vivos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Vivos |
LITTLETON, Colo., May 14, 2024 -- Vivos Therapeutics, Inc. , a leading medical device and technology company specializing in the development and
Read at benzinga.com
Vivos Therapeutics Fundamental Analysis
We analyze Vivos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vivos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vivos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Vivos Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Vivos Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vivos Therapeutics stock to make a market-neutral strategy. Peer analysis of Vivos Therapeutics could also be used in its relative valuation, which is a method of valuing Vivos Therapeutics by comparing valuation metrics with similar companies.
Peers
Vivos Therapeutics Related Equities
BBLG | Bone Biologics | 6.03 | ||||
RPID | Rapid Micro | 1.94 | ||||
NUWE | Nuwellis | 1.60 | ||||
NAOV | NanoVibronix | 1.32 | ||||
TIVC | Tivic Health | 3.85 | ||||
HSCS | Heart Test | 4.92 | ||||
BJDX | Bluejay Diagnostics | 32.90 |
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.